BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 18381102)

  • 1. Antibody and immunomodulatory agents in the treatment of indolent non-Hodgkin's lymphoma.
    LaCasce AS; Freedman AS
    Semin Hematol; 2008 Apr; 45(2):85-9. PubMed ID: 18381102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma.
    Friedberg JW; Freedman AS
    Curr Treat Options Oncol; 2006 Jul; 7(4):276-84. PubMed ID: 16916488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment approaches and novel therapies for lymphoma.
    Leonard JP; Friedberg JW; Hagemeister FB; Levine AM
    Clin Adv Hematol Oncol; 2007 Aug; 5(8 Suppl 12):4-20; quiz 1 p following 20. PubMed ID: 18154235
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
    Maloney DG
    J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
    Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
    Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
    Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
    Prodanovic EM; Korman NJ
    J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.
    Halwani AS; Link BK
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):443-55. PubMed ID: 21417857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
    Nomura S; Ishii K; Kamitsuji Y; Uoshima N; Ishikawa E; Kitayama H; Hayashi K
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):206-12. PubMed ID: 17456632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM
    Adv Pharmacol; 2004; 51():271-93. PubMed ID: 15464914
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic indicators in diffuse, aggressive non-Hodgkin's lymphomas: regulators of growth fraction and programmed cell death.
    Winter JN
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):26-33. PubMed ID: 10561015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
    Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
    In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-targeted therapy for low-grade lymphoma.
    Vose JM
    Semin Hematol; 1999 Oct; 36(4 Suppl 6):15-20. PubMed ID: 10530712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines in lymphoma.
    Levy R
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract]   [Full Text] [Related]  

  • 17. Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL.
    Schmidt HH; Renner H; Linkesch W
    Haematologica; 2004 Nov; 89(11):ECR39. PubMed ID: 15533844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapy of cancer.
    Weiner LM
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):43-51. PubMed ID: 10561017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatments for indolent lymphoma.
    Cheson BD; Gregory SA; Marcus R
    Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
    Vose JM
    Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.